CBD triggered autophagy and cell death in amyloid-expressing cells while showing side effects in healthy cells

CBD induced autophagy and apoptosis specifically in amyloid-beta-expressing cells via LC3B and Caspase-3 pathways, while producing side effects in non-pathological cells. Investigation of CB1 receptors and FAAH showed complex modulation depending on amyloid-beta presence. In C. elegans worm models, FAAH-1 involvement alleviated pharyngeal dysfunction and counteracted weight loss in amyloid-expressing strains.

Multi-model approach combining pharmacological interventions, immunofluorescence imaging, flow cytometry, and biochemical assays. Effects of CBD on amyloid-beta 40 and 42 were examined, along with modulation of CB1 receptors and FAAH with and without amyloid expression. C. elegans (roundworm) models were used to validate in vivo effects.

The finding that CBD has different effects on healthy versus diseased cells is crucial for understanding both its therapeutic potential and safety. If CBD can selectively target amyloid-affected cells while potentially harming healthy ones, this has direct implications for dosing strategies and patient selection in Alzheimer's therapy development.

This selectivity between healthy and diseased cells aligns with the findings of RTHC-06369 (CBD affecting brain copper differently in healthy vs Alzheimer's mice). Together, these studies suggest CBD's biological effects are context-dependent, potentially beneficial in disease states but not without risks in healthy tissue.

Cell culture and worm models are far from human Alzheimer's disease. The side effects in non-pathological cells raise safety concerns that need characterization. The specific CBD concentrations used may not be achievable in human brains. C. elegans do not have a true brain or amyloid plaques.